Literature DB >> 28125158

Chest physiotherapy can affect the lung clearance index in cystic fibrosis patients.

Joerg Grosse-Onnebrink1, Uwe Mellies2, Margarete Olivier2, Claudius Werner1, Florian Stehling2.   

Abstract

OBJECTIVES: The lung clearance index (LCI) is determined by multiple-breath washout lung function (MBW). It is increasingly used as an endpoint in clinical trials. Chest physiotherapy (CP) is part of routine cystic fibrosis (CF) care. Whether the LCI is useful in detecting short-term treatment effects of CP has not been sufficiently investigated. We assessed the short-term influence of CP with highly standardized high-frequency chest wall oscillation (HFCWO) on the LCI in CF patients.
METHODS: In this randomized controlled study, the LCI was obtained in 20 CF patients (7-34 years) hospitalized for infective pulmonary exacerbation prior to and immediately after a single treatment of HFCWO. Twenty-one control group CF patients (7-51 years) received no treatment. We calculated the coefficient of repeatability (CR) to estimate the clinical relevance of possible treatment effects.
RESULTS: HFCWO improved (ie, decreased) the LCI by a median of 0.9 (range -0.45; 3.47; P = 0.002); the LCI decreased in 15 of 20 intervention group patients. In five patients the decrease in LCI exceeded the CR (2.15), indicating a clinically relevant treatment effect; in five patients the LCI increased but did not exceed the CR. The LCI did not change significantly in the control group patients.
CONCLUSIONS: HFCWO can have a short-term decreasing effect on the LCI, but the treatment response is heterogeneous. In future trials using LCI as an endpoint, the timing of CP in relation to MBW should be considered a possible bias.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  chest physiotherapy; coefficient of repeatability; high-frequency chest wall oscillation; lung clearance index; multiple breath washout

Mesh:

Year:  2017        PMID: 28125158     DOI: 10.1002/ppul.23670

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  7 in total

1.  Oscillating devices for airway clearance in people with cystic fibrosis.

Authors:  Lisa Morrison; Stephanie Milroy
Journal:  Cochrane Database Syst Rev       Date:  2020-04-30

Review 2.  Oscillating devices for airway clearance in people with cystic fibrosis.

Authors:  Lisa Morrison; Stephanie Innes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-04

3.  The effect of time-of-day and chest physiotherapy on multiple breath washout measures in children with clinically stable cystic fibrosis.

Authors:  Christian Voldby; Kent Green; Susanne Rosthøj; Thomas Kongstad; Lue Philipsen; Frederik Buchvald; Marianne Skov; Tania Pressler; Per Gustafsson; Kim G Nielsen
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

4.  Deciphering the Impact of Early-Life Exposures to Highly Variable Environmental Factors on Foetal and Child Health: Design of SEPAGES Couple-Child Cohort.

Authors:  Sarah Lyon-Caen; Valérie Siroux; Johanna Lepeule; Philippe Lorimier; Pierre Hainaut; Pascal Mossuz; Joane Quentin; Karine Supernant; David Meary; Laurence Chaperot; Sam Bayat; Flemming Cassee; Sarah Valentino; Anne Couturier-Tarrade; Delphine Rousseau-Ralliard; Pascale Chavatte-Palmer; Claire Philippat; Isabelle Pin; Rémy Slama; The Sepages Study Group
Journal:  Int J Environ Res Public Health       Date:  2019-10-14       Impact factor: 3.390

Review 5.  Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators.

Authors:  Samuel Estabrooks; Jeffrey L Brodsky
Journal:  Int J Mol Sci       Date:  2020-01-10       Impact factor: 5.923

6.  4-week daily airway clearance using oscillating positive-end expiratory pressure versus autogenic drainage in bronchiectasis patients: a randomised controlled trial.

Authors:  Galit Livnat; Naama Yaari; Nili Stein; Lea Bentur; Moneera Hanna; Maya Harel; Yochai Adir; Michal Shteinberg
Journal:  ERJ Open Res       Date:  2021-11-08

7.  An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.

Authors:  Sivagurunathan Sutharsan; Susanne Naehrig; Uwe Mellies; Christian Sieder; Jörg Ziegler
Journal:  BMC Pulm Med       Date:  2020-06-12       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.